Cocrystal Pharma Reports 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Core Viewpoint - Cocrystal Pharma is advancing its antiviral product pipeline, particularly focusing on CDI-988, an oral antiviral candidate for norovirus treatment and prevention, amidst a significant unmet medical need in the market [1][7][18]. Antiviral Product Pipeline Overview - The company utilizes a structure-based drug discovery platform to develop broad-spectrum antivirals that target conserved regions of viral proteins, enhancing efficacy against mutations and reducing side effects [4]. - CDI-988 is designed as a direct-acting oral antiviral targeting the 3CL protease of noroviruses and has potential applications against coronaviruses [3][15]. Norovirus Program - Norovirus causes approximately 685 million cases globally each year, with a $60 billion economic impact, highlighting the urgent need for effective treatments [6]. - CDI-988 is currently undergoing a Phase 1b challenge study at Emory University, with the primary endpoint focused on reducing clinical symptoms [2][7]. Financial Results - For the year ended December 31, 2025, Cocrystal reported a net loss of $8.8 million, a significant reduction from the $17.5 million loss in 2024, indicating improved financial management [17]. - Research and development expenses decreased to $5.1 million in 2025 from $12.5 million in 2024, primarily due to the winding down of previous studies [16]. Influenza Programs - The company is also developing CC-42344, a novel PB2 inhibitor for influenza, which has shown in vitro activity against resistant strains [11][13]. - Influenza poses a major health threat with approximately 1 billion cases annually, leading to significant healthcare costs [10]. Market Potential - The global market for COVID-19 therapeutics is projected to exceed $16 billion annually by the end of 2031, indicating substantial growth opportunities for antiviral treatments [14].